Weeks 1 to 2: More noticeable pain reduction and early improvements in range of motion
GLP-1 therapy may be appropriate for adults who: Have struggled with weight despite lifestyle changes Experience frequent hunger or cravings Have insulin resistance or blood sugar concerns Want physician-guided care rather than online-only programs A medical evaluation is always required, and GLP-1 therapy is not appropriate for everyone
By reducing caloric intake through appetite suppression, improving insulin sensitivity, and directly stimulating hepatic lipid clearance, retatrutide may address multiple drivers of metabolic dysfunction-associated steatotic liver disease (MASLD) terminology increasingly used in UK and European clinical practice, though many NHS and NICE materials continue to use the older designation of non-alcoholic fatty liver disease (NAFLD)
When taken regularly, it helps to mobilise fat, boost metabolism, and stimulate the consumption of fat as an energy source
PMCID: PMC11028008
GHRP-2: D-Ala-D-Nal-Ala-Trp-D-Phe-Lys-NH GHRP-6: His-D-Trp-Ala-Trp-D-Phe-Lys-NH For the full individual profiles, see our GHRP-2 Dosing Guide and GHRP-6 Complete Guide